<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069784</url>
  </required_header>
  <id_info>
    <org_study_id>LTS6035</org_study_id>
    <secondary_id>HOE901/4032</secondary_id>
    <nct_id>NCT00069784</nct_id>
  </id_info>
  <brief_title>The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)</brief_title>
  <acronym>ORIGIN</acronym>
  <official_title>A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the ORIGIN study were:

        -  To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular
           morbidity and/or mortality in people at high risk for vascular disease with either
           Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2
           diabetes;

        -  To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people
           with IFG, IGT or early type 2 diabetes.

      The secondary objectives of the insulin glargine study were to determine if insulin
      glargine-mediated normoglycemia can reduce:

        -  total mortality (all causes);

        -  the risk of diabetic microvascular outcomes;

        -  the rate of progression of IGT or IFG to type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ORIGIN study was conducted by the Population Health Research Institute in Hamilton,
      Ontario (Canada), working in conjunction with the sponsor, and an independent Steering
      Committee.

      Routine visits were to occur at 2, 4, 8, and 16 weeks following randomization, then every
      four months for the rest of the study, for all participants

      The duration of the study was based on the number of events observed (event-driven study) and
      was originally planned to be 5 years. In 2008-2009 ORIGIN's follow-up was extended by
      approximately 2 years, because of published literature of completed studies suggesting that a
      longer period of effective glycemic contrast between treatments might be needed to see an
      effect on cardiovascular events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke</measure>
    <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
    <description>Number of participants with a first occurrence of one of the above events.
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)</measure>
    <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
    <description>Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Mortality (All Causes)</measure>
    <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
    <description>Number of deaths due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)</measure>
    <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
    <description>The composite outcome used to analyze microvascular disease progression contained components of clinical events:
the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);
the development of blindness due to DR;
the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:
doubling of serum creatinine; or
progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG</measure>
    <time_frame>from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)</time_frame>
    <description>The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With Various Types of Symptomatic Hypoglycemia Events</measure>
    <time_frame>on-treatment period (median duration of follow-up: 6.2 years)</time_frame>
    <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.
Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:
the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or
the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With First Occurrence of Any Type of Cancer</measure>
    <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
    <description>Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12537</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Insulin glargine + omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)
One capsule of omega-3 polyunsaturated fatty acids once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)
One capsule of placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care + omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• One capsule of omega-3 polyunsaturated fatty acids once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>• One capsule of placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine (HOE901)</intervention_name>
    <description>Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection</description>
    <arm_group_label>Insulin glargine + omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
    <other_name>Lantus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 polyunsaturated fatty acids (PUFA)</intervention_name>
    <description>Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration</description>
    <arm_group_label>Insulin glargine + omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_label>Standard care + omega-3 polyunsaturated fatty acids</arm_group_label>
    <other_name>Omacor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo gelatin capsules (containing olive oil) for oral administration</description>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
    <arm_group_label>Standard care + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>reusable pen device for insulin injection</intervention_name>
    <arm_group_label>Insulin glargine + omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
    <other_name>OptiPen® Pro 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        I1. Individuals with IFG and/or IGT, or early diabetes, as defined below.

        Glucose tolerance status was determined by a 75 g oral glucose tolerance test (OGTT) that
        was performed fasting (ie, no consumption of food or beverage other than water for at least
        8 hours) at the time of screening for all candidates who were not known to have diabetes.
        The qualifying OGTT could be obtained up to 4 weeks prior to screening provided that
        anti-diabetic therapy (if any) remained unchanged between the qualifying OGTT and the
        screening visit. Two plasma glucose values were drawn during the OGTT - a fasting value
        (FPG) and a value drawn two hours after the 75 g oral glucose load was administered
        (postprandial plasma glucose [PPG]).

        - Impaired glucose tolerance (IGT), defined as a PPG value ≥140 and &lt;200 mg/dL (ie, ≥7.8
        and &lt;11.1 mmol/L), with a FPG &lt;126 mg/dL (7.0 mmol/L).

        OR

        - Impaired fasting glucose (IFG), defined as an FPG ≥110 and &lt;126 mg/dL (≥6.1 and &lt;7
        mmol/L), without diabetes mellitus (PPG must be &lt;200 mg/dL [11.1 mmol/L]).

        OR

        - Early type 2 diabetes, defined as a FPG ≥126 mg/dL (7.0 mmol/L) or a PPG of ≥200 mg/dL
        (11.1 mmol/L), or a previous diagnosis of diabetes, and either:

          -  on no pharmacological treatment (while ambulatory) for at least 10 weeks prior to
             screening, with screening glycated hemoglobin &lt;150% of the upper limit of normal (ULN)
             for the laboratory (eg, &lt;9% if the ULN is 6%)

          -  or taking one oral antidiabetic drug (OAD) from among sulfonylureas (SU), biguanides,
             thiazolidinediones (TZDs), alpha-glucosidase inhibitors (AGIs), and meglitinides
             (MGTs) at a stable dose while ambulatory for at least 10 weeks at the time of
             screening (or for the 10 weeks prior to hospitalization if identified while
             hospitalized for a CV event), with screening glycated hemoglobin &lt;133% of the ULN for
             the laboratory (eg, &lt;8% if the ULN is 6%) if taking this medication at half-maximum
             dose or greater, and glycated hemoglobin &lt;142% of the ULN for the laboratory (eg,
             &lt;8.5% if the ULN is 6%) if taking this medication at less than half-maximum dose.
             Individuals taking combination products containing two or more OADs were not eligible.

        I2. Men or women aged 50 years and older

        I3. At least one of the following CV risk factors:

          -  previous myocardial infarction (MI) (≥ 5 days prior to randomization)

          -  previous stroke (≥ 5 days prior to randomization)

          -  previous coronary, carotid or peripheral arterial revascularization

          -  angina with documented ischemic changes (at least 2 mm ST segment depression on
             electrocardiogram during a Graded Exercise Test [GXT]; or with a cardiac imaging study
             positive for ischemia); or unstable angina with documented ischemic changes (either ST
             segment depression of at least 1 mm or an increase in troponin above the normal range
             but below the range diagnostic for acute myocardial infarction)

          -  microalbuminuria or clinical albuminuria (an albumin: creatinine ratio ≥ 30 μg/mg in
             at least one or timed collection of urine with albumin excretion ≥20 μg/min or ≥30
             mg/24 hours or total protein excretion ≥500 mg/24 hours)

          -  left ventricular hypertrophy by electrocardiogram or echocardiogram

          -  significant stenosis on angiography of coronary, carotid, or lower extremity arteries
             (ie, 50% or more stenosis)

          -  ankle-brachial index &lt; 0.9.

        I4. Provision of signed and dated informed consent prior to any study procedures.

        I5. Ability and willingness to complete study diaries and questionnaires.

        I6. Demonstrated ability to use the self-glucose-monitoring device, and to self-inject
        insulin prior to randomization.

        I7. A negative pregnancy test for all women of childbearing potential (ie, ovulating, pre-
        menopausal, and not surgically sterile) and the agreement of these women to use a reliable
        method of birth control to prevent pregnancy during the duration of the study .

        I8. Willingness to discontinue prior omega-3 PUFA supplements for the duration of the
        study.

        Exclusion criteria

        E1. Type 1 diabetes.

        E2. Requiring ambulatory insulin treatment or uncontrolled or symptomatic hyperglycemia
        that is likely to require the addition of ambulatory insulin therapy or a new antidiabetic
        agent either before or within 2 weeks after randomization.

        E3. Known anti-glutamic acid decarboxylase antibody (anti-GAD Ab) positivity in the past.

        E4. Screening glycated hemoglobin ≥150% of the ULN for the laboratory (eg, ≥9% if the ULN
        is 6%).

        E5. Unwillingness to inject insulin or perform self-monitoring of blood glucose.

        E6. Nonadherence to the run-in requirement to inject placebo insulin and do capillary
        glucose monitoring for at least 4 days prior to randomization.

        E7. Coronary artery bypass grafting (CABG) either planned at the time of screening, or CABG
        within the 4 years prior to screening - however, participants with angina, MI, or stroke
        since a previous CABG will be eligible for randomization, even if the last CABG was within
        4 years.

        E8. Serum creatinine &gt;2.0 mg/dL (176 μmol/L) at screening.

        E9. Active liver disease, or alanine aminotransferase (ALT) or aspartate aminotransferase
        (AST) &gt;2.5 times ULN at screening.

        E10. Chronic or recurrent treatment with systemic corticosteroids, or niacin treatment for
        hyperlipidemia.

        E11. Heart failure of New York Heart Association (NYHA) Functional Class III or IV.

        E12. Expected survival of &lt;3 years for non-CV causes such as cancer.

        E13. Any other factor likely to limit protocol compliance or reporting of adverse events
        (AEs).

        E14. Unwilling or unable to discontinue TZDs.

        E15. Simultaneous participation in any other clinical trial of an active pharmacologic
        agent.

        E16. Unwillingness to permit sites to contact their primary physicians to communicate
        information about the study and the participant's data and treatment assignment.

        E17. History of hypersensitivity to the investigational products.

        E18. Previous randomization in this study.

        E19. A prior heart transplant, or awaiting a heart transplant.

        E20. Known infection with human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel Gerstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and Hamilton Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim Yusuf, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University and Hamilton Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cove</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hamilton</city>
        <country>Bermuda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tatari</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati City</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Aministrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati City</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Bermuda</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <reference>
    <citation>Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008 Jan;155(1):26-32, 32.e1-6. Epub 2007 Nov 26.</citation>
    <PMID>18082485</PMID>
  </reference>
  <reference>
    <citation>Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med. 2010 Feb;27(2):175-80. doi: 10.1111/j.1464-5491.2009.02915.x.</citation>
    <PMID>20546261</PMID>
  </reference>
  <reference>
    <citation>Badings EA, Dyal L, Schoterman L, Lok DJ, Stoel I, Gerding MN, Gerstein HC, Tijssen JG. Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. J Diabetes. 2011 Sep;3(3):232-7. doi: 10.1111/j.1753-0407.2011.00124.x.</citation>
    <PMID>21631894</PMID>
  </reference>
  <reference>
    <citation>Ramachandran A, Riddle MC, Kabali C, Gerstein HC; ORIGIN Investigators. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012 Apr;35(4):749-53. doi: 10.2337/dc11-1918. Epub 2012 Feb 8.</citation>
    <PMID>22323416</PMID>
  </reference>
  <results_reference>
    <citation>ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.</citation>
    <PMID>22686416</PMID>
  </results_reference>
  <results_reference>
    <citation>ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.</citation>
    <PMID>22686415</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2003</study_first_submitted>
  <study_first_submitted_qc>October 3, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2003</study_first_posted>
  <results_first_submitted>December 18, 2012</results_first_submitted>
  <results_first_submitted_qc>December 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2013</results_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired Fasting Glucose (IFG)</keyword>
  <keyword>Impaired Glucose Tolerance (IGT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 575 sites in 40 countries between August 22, 2003 and December 19, 2011. Three sites were closed and data from these sites were not analyzed following site audits and in compliance with rulings from national health authorities.</recruitment_details>
      <pre_assignment_details>The purpose of the factorial design was to efficiently answer two independent scientifically worthwhile questions regarding insulin glargine and omega-3 fatty acids within the context of a single clinical trial. Sample size was determined based on the insulin glargine study objective. Results reported below are those of the insulin glargine study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine</title>
          <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6264">randomized participants = intent-to-treat (ITT) population</participants>
                <participants group_id="P2" count="6273">randomized participants = intent-to-treat (ITT) population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population (Treated)</title>
              <participants_list>
                <participants group_id="P1" count="6231">randomized patients who received at least one dose of insulin glargine</participants>
                <participants group_id="P2" count="6273">patients randomized to standard care arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5052">completed study treatment</participants>
                <participants group_id="P2" count="6273">not applicable (no treatment)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1212"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1090"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glargine</title>
          <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6264"/>
            <count group_id="B2" value="6273"/>
            <count group_id="B3" value="12537"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="7.8"/>
                    <measurement group_id="B2" value="63.5" spread="7.9"/>
                    <measurement group_id="B3" value="63.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4181"/>
                    <measurement group_id="B2" value="3969"/>
                    <measurement group_id="B3" value="8150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2082"/>
                    <measurement group_id="B2" value="2304"/>
                    <measurement group_id="B3" value="4386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Weight</title>
          <description>Due to missing values, N=6256 for insulin glargine and N=6271 for standard care.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.33" spread="16.77"/>
                    <measurement group_id="B2" value="83.13" spread="17.28"/>
                    <measurement group_id="B3" value="83.23" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Body Mass Index</title>
          <description>Due to missing values, N=6251 for insulin glargine and N=6270 for standard care.</description>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.77" spread="5.17"/>
                    <measurement group_id="B2" value="29.88" spread="5.33"/>
                    <measurement group_id="B3" value="29.82" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any previous cardiovascular event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2552"/>
                    <measurement group_id="B2" value="2607"/>
                    <measurement group_id="B3" value="5159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3712"/>
                    <measurement group_id="B2" value="3666"/>
                    <measurement group_id="B3" value="7378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes diagnosis at time of screening</title>
          <description>IFG = Impaired Fasting Glucose defined as a Postprandial Plasma Glucose (PPG) value ≥140 and &lt;200 mg/dL (ie, ≥7.8 and &lt;11.1 mmol/L), with a Fasting Plasma Glucose (FPG) &lt;126 mg/dL (7.0 mmol/L)
IGT = Impaired Glucose Tolerance defined as an FPG ≥110 and &lt;126 mg/dL (≥6.1 and &lt;7 mmol/L), without diabetes mellitus (PPG must be &lt;200 mg/dL [11.1 mmol/L])
OAD = oral antidiabetic drug</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IFG and/or IGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="735"/>
                    <measurement group_id="B2" value="717"/>
                    <measurement group_id="B3" value="1452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Newly diagnosed diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Established diabetes with no OAD treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1414"/>
                    <measurement group_id="B2" value="1467"/>
                    <measurement group_id="B3" value="2881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Established diabetes with one OAD treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3748"/>
                    <measurement group_id="B2" value="3692"/>
                    <measurement group_id="B3" value="7440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclear diabetes status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes for established diabetes patients</title>
          <description>Population of patients with established diabetes. Due to missing values, N=5148 for insulin glargine and N=5141 for standard care.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.50" lower_limit="1.50" upper_limit="7.50"/>
                    <measurement group_id="B2" value="3.50" lower_limit="1.50" upper_limit="7.50"/>
                    <measurement group_id="B3" value="3.50" lower_limit="1.50" upper_limit="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated Hemoglobin A1c (HbA1c)</title>
          <description>Due to missing values, N=6175 for insulin glargine and N=6189 for standard care.</description>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.41" lower_limit="5.81" upper_limit="7.18"/>
                    <measurement group_id="B2" value="6.40" lower_limit="5.81" upper_limit="7.16"/>
                    <measurement group_id="B3" value="6.40" lower_limit="5.81" upper_limit="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>Due to missing values, N=6248 for insulin glargine and N=6266 for standard care.</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.94" lower_limit="6.05" upper_limit="8.20"/>
                    <measurement group_id="B2" value="6.90" lower_limit="6.00" upper_limit="8.20"/>
                    <measurement group_id="B3" value="6.94" lower_limit="6.05" upper_limit="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke</title>
        <description>Number of participants with a first occurrence of one of the above events.
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table.</description>
        <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke</title>
          <description>Number of participants with a first occurrence of one of the above events.
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table.</description>
          <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6264"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with a composite endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1041"/>
                    <measurement group_id="O2" value="1013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: CV death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484"/>
                    <measurement group_id="O2" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: nonfatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: nonfatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The total required number of first coprimary outcomes (2200) assumed that a hazard reduction of 14-16% was clinically significant and controlled the overall experiment-wise Type 1 error at 5% with a power of 80% for each outcome. The total number of participants needed to achieve this number of events within the planned enrollment and treatment periods was ultimately estimated to be 12 500 based on the CURE and HOPE study databases.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6273</p_value>
            <p_value_desc>For the analysis of the two coprimary efficacy outcomes, the overall Type 1 error was partitioned. The first coprimary outcome was tested at 4.4%, whereas the second coprimary outcome was tested at 1% (weighted Hochberg procedure).</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log-rank test stratified by double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.937</ci_lower_limit>
            <ci_upper_limit>1.114</ci_upper_limit>
            <estimate_desc>Hazard ratio (glargine/standard care) estimated by Cox regression model with treatment (glargine, standard care) as factor, stratified by double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)</title>
        <description>Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table.</description>
        <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)</title>
          <description>Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table.</description>
          <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6264"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with a composite endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1792"/>
                    <measurement group_id="O2" value="1727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: CV death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: nonfatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: nonfatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763"/>
                    <measurement group_id="O2" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: hospitalization for HF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>See above additional details provided for the analysis of the first coprimary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2692</p_value>
            <p_value_desc>The second coprimary outcome was tested at 1% (see above additional information for the first coprimary outcome).</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log-rank test stratified by double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.972</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
            <estimate_desc>Hazard ratio (glargine/standard care) estimated by Cox regression model with treatment (glargine, standard care) as factor, stratified by double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mortality (All Causes)</title>
        <description>Number of deaths due to any cause</description>
        <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population, which was all randomized participants, regardless of compliance with the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mortality (All Causes)</title>
          <description>Number of deaths due to any cause</description>
          <population>The analysis was based on the intent-to-treat (ITT) population, which was all randomized participants, regardless of compliance with the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6264"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951"/>
                    <measurement group_id="O2" value="965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.983</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.899</ci_lower_limit>
            <ci_upper_limit>1.076</ci_upper_limit>
            <estimate_desc>Hazard ratio (glargine/standard care) estimated by Cox regression model with treatment (glargine, standard care) as factor, with double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event as covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)</title>
        <description>The composite outcome used to analyze microvascular disease progression contained components of clinical events:
the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);
the development of blindness due to DR;
the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:
doubling of serum creatinine; or
progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine]).</description>
        <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)</title>
          <description>The composite outcome used to analyze microvascular disease progression contained components of clinical events:
the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);
the development of blindness due to DR;
the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:
doubling of serum creatinine; or
progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine]).</description>
          <population>The analysis was based on the intent-to-treat (ITT) population i.e. all randomized participants.
For the endpoint's composition, the numbers only summarize the event when it was the first occurrence of the endpoint. A participant is counted only once within a category. The same participant may appear in different categories.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6264"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with a composite endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1323"/>
                    <measurement group_id="O2" value="1363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: vitrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: laser therapy for DR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: renal transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: serum creatinine doubled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: death due to renal failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint's composition: albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153"/>
                    <measurement group_id="O2" value="1171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.900</ci_lower_limit>
            <ci_upper_limit>1.047</ci_upper_limit>
            <estimate_desc>Hazard ratio (glargine/standard care) estimated by Cox regression model with treatment (glargine, standard care) as factor, with double-blind treatment (omega-3 PUFA, placebo), baseline diabetes diagnosis and previous CV event as covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG</title>
        <description>The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2).</description>
        <time_frame>from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the subgroup of the intent-to-treat (ITT) population without diabetes at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG</title>
          <description>The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2).</description>
          <population>The analysis was based on the subgroup of the intent-to-treat (ITT) population without diabetes at randomization.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="737"/>
                <count group_id="O2" value="719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Odds ratio estimated using Cochran-Mantel-Haenszel (CMH) test method stratified by double-blind treatment (omega-3 PUFA or placebo) and previous cardiovascular event (yes or no).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Various Types of Symptomatic Hypoglycemia Events</title>
        <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant’s diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.
Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:
the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or
the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
        <time_frame>on-treatment period (median duration of follow-up: 6.2 years)</time_frame>
        <population>The population analyzed was the safety population consisting of all randomized and treated patients (who received at least one dose of study drug) for the insulin glargine group and of all randomized patients for the standard care group.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Various Types of Symptomatic Hypoglycemia Events</title>
          <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant’s diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.
Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:
the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or
the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.</description>
          <population>The population analyzed was the safety population consisting of all randomized and treated patients (who received at least one dose of study drug) for the insulin glargine group and of all randomized patients for the standard care group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6231"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with hypoglycemia events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3597"/>
                    <measurement group_id="O2" value="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with non-severe hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3533"/>
                    <measurement group_id="O2" value="1582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with confirmed non-severe hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2581"/>
                    <measurement group_id="O2" value="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with severe hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With First Occurrence of Any Type of Cancer</title>
        <description>Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee.</description>
        <time_frame>from randomization until study cut-off date (median duration of follow-up: 6.2 years)</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Occurrence of Any Type of Cancer</title>
          <description>Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee.</description>
          <population>The analysis was based on the intent-to-treat (ITT) population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6264"/>
                <count group_id="O2" value="6273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559"/>
                    <measurement group_id="O2" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were assessed through the study. The median duration of follow-up was 6.2 years.</time_frame>
      <desc>Aside from hypoglycemia and cancer, serious AEs were only captured if the event was considered related to a study drug. Non-serious AEs were only captured if the event resulted in some modification (suspension, alteration or cessation) in the dose of a study drug. This creates a bias for the comparison between insulin glargine and standard care.</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine</title>
          <description>Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Standard care with or without omega-3 polyunsaturated fatty acids</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pericardial disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Eversion of lacrimal punctum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Duodenal varices</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pancreatolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Arteriogram carotid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ureteroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cystoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant non-resectable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pseudomyxoma peritonei</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsies multiple</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cholecystostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Intestinal resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Urethral dilation procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Colporrhaphy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Parotidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>&quot;The Steering Committee will be responsible for preparing summaries of the study results for publication in the medical literature, and will have the right to submit such summaries for publication after a review by the sponsor. In such cases comments from the sponsor to the Steering Committee are to be provided within 15 working days. All comments will be carefully considered by the Steering Committee who nevertheless have the final decision on the content of the manuscript.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi</organization>
      <email>Contact_US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

